Following on from the commercialisation update provided in November, ProAxsis is pleased to report the first sale of NEATstik®, the company’s novel sputum-based point-of-care test, to a research laboratory conducting …

ProAxsis Limited (www.proaxsis.com) today announces that it has successfully registered a CE Mark for its ProteaseTag® Active Plasmin Immunoassay. This novel technology will enable academic and pharmaceutical researchers to specifically …

ProAxsis’ ProteaseTag® technology will again be featured at the Winter meeting of the British Thoracic Society, which takes place between December 6th-8th at the Queen Elizabeth II Conference Centre, in London. …

ProAxsis Limited has contracted with National Jewish Health (NJH), the leading respiratory hospital in the United States, to validate the company’s ProteaseTag® point-of-care technology for real-time management of small …

ProAxsis today announces that the company has appointed Diagenics Limited as the distributor for its ProteaseTag® Active Neutrophil Elastase Immunoassay in Great Britain and Ireland. Founded in 1994, Diagenics supply …

ProAxsis Ltd today announces that the company has signed a partnership agreement to develop activity-based immunoassays for two key respiratory proteases, utilising its ProteaseTag® technology. The partner is a …

ProAxsis will be presenting further data on its ProteaseTag® technology, at the European Respiratory Society Conference, which takes place between September 9th-13thin Milan, Italy. The company has had four abstracts …